166 related articles for article (PubMed ID: 23946126)
1. Cisplatin otoprotection using transtympanic L-N-acetylcysteine: a pilot randomized study in head and neck cancer patients.
Yoo J; Hamilton SJ; Angel D; Fung K; Franklin J; Parnes LS; Lewis D; Venkatesan V; Winquist E
Laryngoscope; 2014 Mar; 124(3):E87-94. PubMed ID: 23946126
[TBL] [Abstract][Full Text] [Related]
2. Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy.
Riga MG; Chelis L; Kakolyris S; Papadopoulos S; Stathakidou S; Chamalidou E; Xenidis N; Amarantidis K; Dimopoulos P; Danielides V
Am J Clin Oncol; 2013 Feb; 36(1):1-6. PubMed ID: 22134515
[TBL] [Abstract][Full Text] [Related]
3. Are intratympanic injections of N-acetylcysteine and methylprednisolone protective against Cisplatin-induced ototoxicity?
Saliba I; El Fata F; Ouelette V; Robitaille Y
J Otolaryngol Head Neck Surg; 2010 Jun; 39(3):236-43. PubMed ID: 20470667
[TBL] [Abstract][Full Text] [Related]
4. Transtympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-Induced Ototoxicity: Double Blind Randomized Clinical Trial.
Sarafraz Z; Ahmadi A; Daneshi A
Int Tinnitus J; 2018 Jun; 22(1):40-45. PubMed ID: 29993216
[TBL] [Abstract][Full Text] [Related]
5. Intratympanic dexamethasone to prevent cisplatin ototoxicity: a guinea pig model.
Murphy D; Daniel SJ
Otolaryngol Head Neck Surg; 2011 Sep; 145(3):452-7. PubMed ID: 21521888
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intermittent intratympanic steroid injection and near-continual transtympanic steroid perfusion as salvage treatments for sudden sensorineural hearing loss.
Chou YF; Chen PR; Kuo IJ; Yu SH; Wen YH; Wu HP
Laryngoscope; 2013 Sep; 123(9):2264-9. PubMed ID: 23804460
[TBL] [Abstract][Full Text] [Related]
7. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Rasch CR; Tange RA; Balm AJ; Dreschler WA
Audiol Neurootol; 2006; 11(5):318-30. PubMed ID: 16983183
[TBL] [Abstract][Full Text] [Related]
8. Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.
Van Wijk F; Staecker H; Keithley E; Lefebvre PP
Audiol Neurootol; 2006; 11(6):357-65. PubMed ID: 16988499
[TBL] [Abstract][Full Text] [Related]
9. The role of intratympanic lactate injection in the prevention of cisplatin-induced ototoxicity.
Nader ME; Théorêt Y; Saliba I
Laryngoscope; 2010 Jun; 120(6):1208-13. PubMed ID: 20513041
[TBL] [Abstract][Full Text] [Related]
10. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
[TBL] [Abstract][Full Text] [Related]
11. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
12. Targeted amelioration of cisplatin-induced ototoxicity in guinea pigs.
Mohan S; Smyth BJ; Namin A; Phillips G; Gratton MA
Otolaryngol Head Neck Surg; 2014 Nov; 151(5):836-9. PubMed ID: 25078416
[TBL] [Abstract][Full Text] [Related]
13. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study.
Dispenza F; Amodio E; De Stefano A; Gallina S; Marchese D; Mathur N; Riggio F
Eur Arch Otorhinolaryngol; 2011 Sep; 268(9):1273-8. PubMed ID: 21327728
[TBL] [Abstract][Full Text] [Related]
14. L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity.
Feghali JG; Liu W; Van De Water TR
Laryngoscope; 2001 Jul; 111(7):1147-55. PubMed ID: 11568534
[TBL] [Abstract][Full Text] [Related]
15. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial.
Lim HJ; Kim YT; Choi SJ; Lee JB; Park HY; Park K; Choung YH
Otolaryngol Head Neck Surg; 2013 Jan; 148(1):121-7. PubMed ID: 23077155
[TBL] [Abstract][Full Text] [Related]
17. Can acetylcysteine ameliorate cisplatin-induced toxicities and oxidative stress without decreasing antitumor efficacy? A randomized, double-blind, placebo-controlled trial involving patients with head and neck cancer.
Visacri MB; Quintanilha JCF; de Sousa VM; Amaral LS; de F L Ambrósio R; Calonga L; Curi SFBB; de T Leme MF; Chone CT; Altemani JMC; Mazzola PG; Malaguti C; Vercesi AE; Lima CSP; Moriel P
Cancer Med; 2019 May; 8(5):2020-2030. PubMed ID: 30977273
[TBL] [Abstract][Full Text] [Related]
18. Effect of noise conditioning on cisplatin-induced ototoxicity: a pilot study.
Theneshkumar S; Lorito G; Giordano P; Petruccelli J; Martini A; Hatzopoulos S
Med Sci Monit; 2009 Jul; 15(7):BR173-7. PubMed ID: 19564816
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
Rolland V; Meyer F; Guitton MJ; Bussières R; Philippon D; Bairati I; Leclerc M; Côté M
J Otolaryngol Head Neck Surg; 2019 Jan; 48(1):4. PubMed ID: 30651130
[TBL] [Abstract][Full Text] [Related]
20. Sudden sensorineural hearing loss: results of intratympanic steroids as salvage treatment.
Dispenza F; De Stefano A; Costantino C; Marchese D; Riggio F
Am J Otolaryngol; 2013; 34(4):296-300. PubMed ID: 23357592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
